Company Overview of DermTech International, Inc.
DermTech International, Inc., a biotechnology company, develops and commercializes qPCR assays for skin samples collected non-invasively using adhesive tape biopsy methods. It offers non-invasive molecular diagnostics for disease detection. The company’s assays can analyze multiple gene targets to assess their level of RNA expression. Its MelDTect melanoma detection test is based on the Epidermal Genetic Information Retrieval approach that employs a patented adhesive-based method to obtain cells from the upper layer of the skin and genetic analysis to determine the probability of disease. The company develops molecular biology assays to identify, diagnose, and analyze melanoma, prostate canc...
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 1996
Key Executives for DermTech International, Inc.
Director of Business Administration
Senior Director Molecular Biology
Director of Clinical Laboratory Operations
Compensation as of Fiscal Year 2013.
DermTech International, Inc. Key Developments
DermTech International, Inc. Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014
Dec 23 13
DermTech International, Inc. Presents at The 7th Annual OneMedForum San Francisco 2014 Conference, Jan-13-2014 . Venue: Westin San Francisco Market Street, San Francisco, California, United States.
Dermtech Initiates Commercial Validation Testing of its Proprietary Pigmented Lesion Assay
Sep 25 13
DermTech announced that it has initiated commercial validation testing of its proprietary pigmented lesion assay. The company recently completed the build-out of a commercial laboratory space on 11099 N. Torrey Pines Road, La Jolla, CA. The analytical and clinical validation studies are required for regulatory certification following CLIA (Clinical Laboratory Improvement Amendments) requirements. The CLIA federal regulatory standards require clinical laboratories to establish and document their performance specifications for laboratory-developed tests to ensure accurate and precise results prior to implementation of the test. The performance characteristics that must be established include accuracy, precision, reportable range, reference interval, analytical sensitivity, and analytical specificity. A recent Series B financing led by Jacobs Investment Company LLC will be partially used to complete these efforts.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 8, 2013
Most Searched Private Companies
Sponsored Financial Commentaries